INTRODUCTION {#s1}
============

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a protein that can modulate cell survival and cell cycle progression \[[@R1]\]. In healthy physiological conditions, PTEN can control smooth muscle differentiation \[[@R2]\], mediate angiogenesis \[[@R3]\], maintain Treg cell stability \[[@R4]\], and coordinate retinal neurogenesis \[[@R5]\]. However, PTEN is a tumor suppressor that is commonly down-regulated in many types of cancer \[[@R6]\], including non-small cell lung cancer (NSCLC) \[[@R7], [@R8]\]. Indeed, inactivation of PTEN can augment invasiveness and anchorage independent growth of NSCLC cells \[[@R9]\]. In addition, in some animal models, PTEN inactivation also accelerates tumorigenesis \[[@R10]\]. On the other hand, exogenously imported PTEN can suppress lung tumorigenesis \[[@R11]\]. Similarly, PTEN upregulation can inhibit NSCLC cell growth and promote partial apoptosis \[[@R12]\].

While many histopathology research studies reported that PTEN downregulation correlates with unfavorable survival prognosis in NSCLC patients \[[@R13]--[@R16]\], some studies reached the opposite conclusion \[[@R17], [@R18]\]. Therefore results in this field seem to be inconsistent. One problem is that most studies assessing the effects of PTEN expression in NSCLC were limited by small sample sizes. Here, we performed a systematic review and statistical meta-analysis of the literature to draw conclusions regarding the prognostic value of PTEN downregulation in NSCLC patients.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

Our initial database search identified 237 potentially relevant records. After the duplicates were removed, 77 records remained, of which 54 were excluded because they failed to meet our inclusion criteria (see Materials and Methods). In the end, a total of 23 studies \[[@R13]--[@R35]\] were included in this systematic review (Figure [1](#F1){ref-type="fig"}). The main characteristics of these studies are summarized in Table [1](#T1){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"}. In total, 2,505 NSCLC patients were included in our meta-analysis. According to the different survival outcomes, patients from the 23 eligible studies were divided into 27 datasets: 20 for overall survival (OS), four for disease-free survival (DFS) and three for progression-free survival (PFS) (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). The Newcastle-Ottawa Quality Assessment Scale (NOS) scores of the included studies ranged from five to eight (with a mean value of 6.22), indicating that these studies were of moderate to high quality ([Table S2](#SD1){ref-type="supplementary-material"}).
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###### Main characteristics of eligible studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author              Year   Region   Cases   Expression   Method   Treatment             Outcome   Analysis       HR estimation     Follow-up time
  ------------------------- ------ -------- ------- ------------ -------- --------------------- --------- -------------- ----------------- ---------------------------------------------------
  Shen H \[[@R13]\]         2016   China    51      Protein      IHC      Surgery/\             OS        Univariate     Survival curves   The max follow-up time was 66.2 months
                                                                          EGFR-TKI                                                         

  Wang J \[[@R14]\]         2015   China    92      Protein      IHC      Surgery               OS        Univariate     Survival curves   Median 28 months (range, 3 to 98 month)

  Tang YA \[[@R15]\]        2015   Taiwan   133     Protein      IHC      Surgery               OS        Univariate     Survival curves   The max follow-up time was 126.8 months

  Li XB \[[@R16]\]          2015   China    68      Protein      IHC      Surgery               OS        Multivariate   Reported data     Median 12.5 months (range, 3.6 to 40.6 months)

  Ji Y \[[@R19]\]           2014   China    67      Protein      IHC      Surgery               OS        Multivariate   Reported data     The max follow-up time was 40 months

  Shen H \[[@R20]\]         2014   China    46      Protein      IHC      Surgery/\             OS        Univariate     Survival curves   The max follow-up time was 66 months
                                                                          EGFR-TKI                                                         

  Hu J \[[@R21]\]           2012   China    114     Protein      IHC      Surgery               OS        Univariate     Reported data     Median 40.10 months (range, 2.23 to 67.77 months)

  Wang L \[[@R22]\]         2012   China    78      Protein      IHC      Surgery               PFS       Univariate     Survival curves   The max follow-up time was 24 months

  An SJ \[[@R23]\]          2012   China    97      Protein      IHC      Surgery               OS        Univariate     Survival curves   Median 53.9 months

  Shih MC \[[@R24]\]        2012   Taiwan   119     Protein      IHC      Surgery               OS        Univariate     Survival curves   The max follow-up time was 120 months

  Shih MC \[[@R24]\]        2012   Taiwan   119     Protein      IHC      Surgery               DFS       Univariate     Survival curves   The max follow-up time was 120 months

  Yanagawa N \[[@R25]\]     2012   Canada   152     Protein      IHC      Surgery               DFS       Multivariate   Reported data     Median 28.56 months (range, 0.84 to 71.64 months)

  Yoo SB \[[@R26]\]         2011   Korea    288     Protein      IHC      Surgery/\             PFS       Multivariate   Reported data     Median 44 months (range, 1 to 84 months)
                                                                          Chemotherapy/\                                                   
                                                                          Radiation therapy/\                                              
                                                                          EGFR-TKI                                                         

  Cetin Z \[[@R27]\]        2010   Turkey   50      Protein      WB       Surgery               OS        Univariate     Survival curves   The max follow-up time was 34.2 months

  Buckingham L \[[@R17]\]   2010   USA      132     Protein      IHC      Surgery               OS        Univariate     Survival curves   The max follow-up time was 60.2 months

  Wang C \[[@R28]\]         2009   China    249     Protein      IHC      Surgery               OS        Multivariate   Reported data     The max follow-up time was 83 months

  Inamura K \[[@R18]\]      2007   Japan    115     mRNA         PCR      Surgery               OS        Univariate     Survival curves   The max follow-up time was 109.7 months

  Zheng H \[[@R29]\]        2007   Japan    143     Protein      IHC      NR                    OS        Univariate     Survival curves   Mean 20.6 months (range, 1 to 144 months)

  Lim WT \[[@R30]\]         2007   USA      25      Protein      IHC      Gefitinib             PFS       Univariate     Survival curves   The max follow-up time was 100.8 months

  Lim WT \[[@R30]\]         2007   USA      25      Protein      IHC      Gefitinib             OS        Univariate     Survival curves   The max follow-up time was 100.8 months

  Endoh H \[[@R31]\]        2006   Japan    78      mRNA         PCR      Surgery/\             OS        Univariate     Reported data     Median 4 months (range, 0.8 to 31.3 months)
                                                                          Chemotherapy/\                                                   
                                                                          Gefitinib                                                        

  Tang JM \[[@R32]\]        2006   China    102     Protein      IHC      Surgery               OS        Multivariate   Reported data     Median 25.5 months (range, 3 to 60 months)

  Ferraro B \[[@R33]\]      2005   USA      125     mRNA         PCR      Surgery               DFS       Univariate     Survival curves   Median 101 months (range, 39 to 161 months)

  Ferraro B \[[@R33]\]      2005   USA      125     mRNA         PCR      Surgery               OS        Univariate     Survival curves   Median 101 months (range, 39 to 161 months)

  Bepler G \[[@R34]\]       2004   USA      77      mRNA         PCR      Surgery               OS        Multivariate   Reported data     Median 39.7 months (range, 2.0 to 106.1 months)

  Bepler G \[[@R34]\]       2004   USA      77      mRNA         PCR      Surgery               DFS       Univariate     Survival curves   Median 39.7 months (range, 2.0 to 106.1 months)

  Goncharuk VN \[[@R35]\]   2004   USA      104     Protein      IHC      Surgery               OS        Univariate     Survival curves   Mean 52 months (range, 5 to 127 months)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IHC: Immunohistochemistry; WB: Western blot; PCR: Polymerase chain reaction; NR: No report; EGFR-TKI: Epidermal growth factor receptor-tyrosine kinase inhibitor; OS: Overall survival; DFS: disease-free survival; PFS: progression-free survival; HR: Hazard ratio.

Meta-analysis of OS {#s2_2}
-------------------

The pooled result from 20 datasets revealed significant association between decreased PTEN expression and poor OS in patients with NSCLC (HR = 0.48, 95% CI: 0.43--0.54, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Meanwhile, no obvious heterogeneity was found (*I^2^* = 33.1%, *P* = 0.076). By successively omitting each study, sensitivity analysis was performed to evaluate the impact of every study on the pooled HR. Results showed that the pooled HRs were no different with the exclusion of any individual study, implying that the result of the meta-analysis of OS is stable (Figure [3](#F3){ref-type="fig"}).
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![Sensitivity analysis on the relationship between decreased expression of PTEN and OS in patients with NSCLC\
CI = confidence interval.](oncotarget-07-57832-g003){#F3}

Subgroup analyses were performed depending on protein and mRNA expression, type of analysis (univariate vs. multivariate), population (Asian vs. non Asian), number of cases (less than 100 vs. more than 100) and year (after 2010 vs. before 2010). Results showed that decreased expression of PTEN protein had an unfavorable prognostic value in NSCLC patients (HR = 0.46, 95% CI: 0.39--0.53, *P* \< 0.001). However, although decreased expression of PTEN mRNA also correlated with poor OS in patients with NSCLC, its value did not reach statistical significance (HR = 0.60, 95% CI: 0.34--1.07, *P* = 0.084) ([Figure S1](#SD1){ref-type="supplementary-material"}, Table [2](#T2){ref-type="table"}). The results from analyzing both the univariate and multivariate analysis subgroups indicated that decreased expression of PTEN was associated with poor OS in NSCLC patients (HR = 0.47, 95% CI: 0.37--0.59, *P* \< 0.001; HR = 0.47, 95% CI: 0.39--0.56, *P* \< 0.001, respectively) ([Figure S2](#SD1){ref-type="supplementary-material"}, Table [2](#T2){ref-type="table"}). In addition, the pooled results of other subgroup analyses showed a similar prognostic value for decreased expression of PTEN ([Figures S3--S5](#SD1){ref-type="supplementary-material"}, Table [2](#T2){ref-type="table"}).

###### Meta-analysis results for the association between decreased expression of PTEN and OS in patients with NSCLC

  Categories                                            Subgroups       Number of datasets     HR (95% CI)            *P*-Value   Heterogeneity   
  ----------------------------------------------------- --------------- ---------------------- ---------------------- ----------- --------------- -------
  **All [^F^](#tfn_001){ref-type="table-fn"}**                          20                     0.483 (0.429--0.543)   \< 0.001    33.1%           0.076
  **Expression [^R^](#tfn_002){ref-type="table-fn"}**   Protein         16                     0.456 (0.389--0.535)   \< 0.001    24.9%           0.173
  mRNA                                                  4               0.604 (0.340--1.070)   0.084                  50.4%       0.110           
  **Analysis [^R^](#tfn_002){ref-type="table-fn"}**     Univariate      15                     0.466 (0.368--0.589)   \< 0.001    47.8%           0.020
  Multivariate                                          5               0.469 (0.393--0.558)   \< 0.001               0.0%        0.852           
  **Population [^R^](#tfn_002){ref-type="table-fn"}**   Asian           15                     0.461 (0.376--0.566)   \< 0.001    49.0%           0.017
  Non Asian                                             5               0.502 (0.372--0.677)   \< 0.001               0.0%        0.929           
  **Cases [^R^](#tfn_002){ref-type="table-fn"}**        Less than 100   10                     0.396 (0.311--0.503)   \< 0.001    0.0%            0.721
  More than 100                                         10              0.523 (0.421--0.649)   \< 0.001               51.9%       0.028           
  **Year [^R^](#tfn_002){ref-type="table-fn"}**         After 2010      9                      0.412 (0.307--0.554)   \< 0.001    56.0%           0.020
  Before 2010                                           11              0.506 (0.436--0.589)   \< 0.001               0.0%        0.514           

For fixed-effects model;

for random-effects model;

HR: Hazard ratio; CI: Confidence intervals.

Meta-analysis of DFS/PFS {#s2_3}
------------------------

The pooled result from four datasets of DFS revealed that decreased expression of PTEN was associated with unfavorable DFS in patients with NSCLC (HR = 0.57, 95% CI: 0.44--0.73, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). Similarly, the pooled result from three datasets of PFS showed that decreased expression of PTEN also had an unfavorable prognostic value for PFS in NSCLC patients (HR = 0.48, 95% CI: 0.26--0.88, *P* = 0.018) (Figure [4](#F4){ref-type="fig"}).
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Publication bias {#s2_4}
----------------

Both Begg\'s and Egger\'s test were used to evaluate the publication bias of the meta-analysis of OS. The result of Egger\'s test showed no publication bias (*P* = 0.169) while Begg\'s test indicated that publication bias might exist (*P* = 0.012). We used the trim-and-fill method to estimate the influence of potential publication bias. As a result, three theoretical studies were added in the meta-analysis of OS ([Figure S6](#SD1){ref-type="supplementary-material"}). The recalculated pooled result did not change significantly (HR = 0.51, 95% CI: 0.45--0.57, *P* \< 0.001), indicating the stability of the result.

DISCUSSION {#s3}
==========

All 23 studies we analyzed met specific inclusion criteria and had moderate to high quality according to their NOS scores. Overall, 2,505 NSCLC patients were included and the survival data were organized based on overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS). The combined results demonstrated that decreased expression of PTEN correlated with poor OS in NSCLC patients. What\'s more, we found that decreased expression of PTEN also indicated a poor prognosis for DFS and PFS in patients with NSCLC.

In our meta-analysis, the results from analyzing both the univariate and multivariate subgroups indicated that decreased expression of PTEN was associated with poor OS in patients with NSCLC. However, multivariate analysis ruled out the compounding effects from other clinicopathological factors such as sex, age, tumor size, nodal status and stage, among others \[[@R16], [@R19], [@R28], [@R32], [@R34]\]. Thus, according to the pooled result from analyzing the multivariate analysis subgroup, expression of PTEN may be considered to be an independent factor of poor prognosis in NSCLC patients. While decreased expression of PTEN protein correlated with poor OS in patients with NSCLC, decreased expression of PTEN mRNA did not. This is not surprising since mRNA levels from an expressed gene do not usually predict the corresponding protein levels \[[@R36], [@R37]\]. Immunohistochemistry is used as a complementary diagnostic method in 95% of cancer cases \[[@R38]\] because it can benefit surgical and therapeutic decisions at a low cost. Therefore, we recommend clinicians to use PTEN protein expression detected by immunohistochemistry as a prognostic factor to treat NSCLC patients.

Prior to our study, two meta-analyses had been performed to evaluate the association between PTEN expression and the survival of cancer patients. According to the combined results of nine original studies, Chen J. *et al.* concluded that reduced PTEN expression correlated with poor OS in patients with gastric cancer \[[@R39]\]. On the other hand, the meta-analysis of 14 original studies by Cai J. *et al.* found that the expression of PTEN had no prognostic value for OS in patients with epithelial ovarian cancer \[[@R40]\]. However, in our current meta-analysis, the combined results from 20 original studies showed that decreased expression of PTEN was indeed associated with poor OS in NSCLC patients. These results suggest that the correlation between PTEN expression and OS in cancer patients may differ depending on cancer type.

Among our eligible studies, four \[[@R24], [@R25], [@R33], [@R34]\] reported statistics for DFS and three \[[@R22], [@R26], [@R30]\] for PFS. Most of the patients in such studies had undergone surgical resection. Yoo S.B. *et al.* \[[@R26]\] reported a cohort of 288 consecutive NSCLC patients who underwent surgical resection and further received post operative adjuvant chemotherapy and radiation therapy. Among them, some patients received additional EGFR-TKIs, such as gefitinib or erlotinib \[[@R26]\]. In addition, Lim W.T. *et al.* \[[@R30]\] also reported a cohort of NSCLC patients that had only been treated with gefitinib. Overall, our results combining data from both of the aforementioned studies revealed that decreased expression of PTEN was associated with a shorter DFS as well as a shorter PFS. This means that in addition to the prognostic value of decreased PTEN expression on OS, PTEN expression levels can also inform on the effect of treatment for patients with NSCLC.

Tumor suppression by PTEN depends on its negative regulation of the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway \[[@R41]\]. Thus, PTEN is regarded as the controller of this pathway \[[@R42]\]. Consequently, when the expression of PTEN is decreased, either inhibiting PI3K or controlling the PI3K-Akt-mTOR pathway in other ways can supplement PTEN\'s tumor suppression \[[@R43]--[@R46]\]. Therefore, we consider that NSCLC patients with decreased expression of PTEN suffer from a subtype of lung cancer and might benefit from individualized treatment plans.

Several limitations should be noticed in our meta-analysis. One of the main limitations is the potential publication bias, stemming from published results being predominantly positive, since all of our included studies were retrospectively designed. Furthermore, patient populations in our study were limited, as patients came only from Asia and North America. Additionally, some of the survival data we used were extracted from survival curves, which may introduce subjective bias. Finally, the studies reporting DFS and PFS were few in number. Therefore, further studies without these biases might strengthen our conclusions. Nonetheless, our meta-analyses showed that decreased expression of PTEN predicted a shorter OS, DFS and PFS in the populations of patients with NSCLC analyzed.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We systematically searched in the online Scopus, Web of Science, PubMed and Embase databases (updated until May 22, 2016) with the restrictions of English language and original article. Two investigators (Jian Xiao and Bi-Xiu He) independently screened all titles and abstracts to identify eligible studies. The search terms used included "PTEN", "NSCLC" and derivative terms (File S1). Manual searches of the included studies and published reviews were also conducted.

Study selection {#s4_2}
---------------

In this meta-analysis, studies were selected according to the following criteria: (1) original studies measured the PTEN expression in patients with NSCLC; (2) reported the correlation between PTEN expression and patient survival; (3) reported the hazard ratios (HRs), and their corresponding 95% confidence intervals (CIs) could be obtained. Of note, we would include the most complete report if the same authors reported repeated results. However, unpublished studies, meeting abstracts, case reports, comments, letters, meta-analyses and literature reviews were excluded.

Data extraction {#s4_3}
---------------

Two raters independently extracted the primary information using a standardized form and disagreements were discussed until a consensus was reached. Except for the HRs and their corresponding 95% CIs, the following information categories were also extracted: first author, year of publication, region of population, number of cases, PTEN expression, test method, survival outcome, analysis method, HR estimation, follow-up time and cut-off value. When both multivariate and univariate analyses of the survival results were reported, we extracted the HRs and their corresponding 95% CIs from multivariate analyses. However, when HR and its corresponding 95% CI were not reported as calculated data, they were estimated using the previously reported methods \[[@R47], [@R48]\], according to other relevant information (e.g., survival curves).

Quality assessment {#s4_4}
------------------

The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of the included studies and was conducted by two independent investigators. Disagreements were resolved by discussion. In brief, NOS is comprised of three parameters of quality: selection, comparability, and outcome assessment. Furthermore, each study received a total score between 0 and 9, with a NOS score of 7 or above considered as high quality and a NOS score of 3 or below considered as low quality \[[@R48]--[@R50]\]. Details of the quality assessment of included studies are provided in File S2 and [Table S2](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#s4_5}
--------------------

We used Stata 12.0 (StataCorp LP) and R software (<https://www.r-project.org/>) to perform all statistical analyses. HRs and their corresponding 95% CIs were calculated for all of the survival outcomes. When the pooled HR was lower than 1, we considered that the decreased expression of PTEN was associated with unfavorable survival in patients with NSCLC. Heterogeneity analysis was conducted using Cochran\'s *Q* test and Higgins\' I-squared statistic and Heterogeneity was defined either as *I^2^* \> 50% or *P* \< 0.05. A random-effects model was used when heterogeneity was present; otherwise, the fixed-effects model was used. The stability of the pooled HR results was assessed by the sensitivity analysis. Publication bias was evaluated using Begg\'s and Egger\'s tests. If publication bias existed, we applied the trim-and-fill method. For all of our results, *P* \< 0.05 (two-tailed) was defined to be statistically significant.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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